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Biological functionIt is more than 50 years since the lysosome was discovered. Since then its hydrolytic machinery, including
proteases and other hydrolases, has been fairly well identiﬁed and characterized. Among these are the cyste-
ine cathepsins, members of the family of papain-like cysteine proteases. They have unique reactive-site prop-
erties and an uneven tissue-speciﬁc expression pattern. In living organisms their activity is a delicate balance
of expression, targeting, zymogen activation, inhibition by protein inhibitors and degradation. The speciﬁcity
of their substrate binding sites, small-molecule inhibitor repertoire and crystal structures are providing new
tools for research and development. Their unique reactive-site properties have made it possible to conﬁne the
targets simply by the use of appropriate reactive groups. The epoxysuccinyls still dominate the ﬁeld, but now
nitriles seem to be the most appropriate “warhead”. The view of cysteine cathepsins as lysosomal proteases is
changing as there is now clear evidence of their localization in other cellular compartments. Besides being
involved in protein turnover, they build an important part of the endosomal antigen presentation. Together
with the growing number of non-endosomal roles of cysteine cathepsins is growing also the knowledge of
their involvement in diseases such as cancer and rheumatoid arthritis, among others. Finally, cysteine cathep-
sins are important regulators and signaling molecules of an unimaginable number of biological processes. The
current challenge is to identify their endogenous substrates, in order to gain an insight into the mechanisms
of substrate degradation and processing. In this review, some of the remarkable advances that have taken
place in the past decade are presented. This article is part of a Special Issue entitled: Proteolysis 50 years
after the discovery of lysosome.
© 2011 Elsevier B.V. Open access under CC BY-NC-ND license.1. Introduction
In 1955, Christian de Duve discovered a distinct class of a single
population of homogeneous granules containing ﬁve acidic hydro-
lases. It was proposed to refer to these granules as lysosomes, because
of their richness in terms of hydrolytic enzymes [1]. The ﬁnding that
these hydrolases act on different substrates suggested that the lyso-
somes, also known as “suicide bags”, might play a role in intracellular
digestion at acidic pH. Lysosomes were then discovered in several cell
types and found to be involved in the degradation of extracellular ma-
terial taken up by endocytosis and intracellular material taken up bylysis 50 years after the discov-
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accepted [2–5]. In parallel, based on these ﬁndings, numerous lyso-
somal hydrolases were isolated, characterized, and their mechanisms
of action were established. With the discovery of the ubiquitin-
proteasome system [6] it was concluded that there are twomajor sys-
tems for intracellular protein degradation: the lysosomal system and
the ubiquitin-proteasome system. It is well established that the endo-
somal/lysosomal system has numerous functions in normal and path-
ological processes, including the survival function [7].
In the lysosomal system, protein degradation is a result of the
combined random and limited action of various proteases (also
termed peptidases or proteolytic enzymes). In order to achieve the ef-
ﬁcient degradation of biological macromolecules within the lyso-
somes, lysosomes contain a number of diverse hydrolases, including
proteases, amylases, lipases and nucleases. Among the approximately
50 known lysosomal hydrolases, of particular importance are the
aspartic, serine and cysteine proteases [8]. In addition to the aspartic
cathepsin D, cysteine cathepsins have a key role among the lysosomal
proteases. They belong to the clan CA of cysteine peptidases, which
are widely distributed among living organisms, and represent one of
the most investigated groups of enzymes. More speciﬁcally, they are
members of the C1 family of papain-like enzymes, the largest and
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among others, papain and related plant enzymes, proteases in para-
sites and helminths, insect-homologs of papain, trematode cysteine
proteases, viral proteases, and lysosomal cysteine cathepsins [9].
This chapter will focus on human cysteine cathepsins, which have
been the subject of numerous reviews in the past [10–18].
2. Cysteine cathepsins
The name cathepsin, which is derived from the Greek kathepsein
(to digest), was proposed for the protease that was active in a slightly
acidic environment [19]. Later, the name cathepsin was introduced
for the serine proteases cathepsins A and G, the aspartic proteases ca-
thepsins D and E, and the lysosomal cysteine cathepsins. There are 11
human cysteine cathepsins, i.e., the cathepsins B, C, F, H, K, L, O, S, V, X
and W, existing at the sequence level; this was conﬁrmed by a bioin-
formatic analysis of the draft sequence of the human genome [20].
Lysosomal cathepsins require a reducing, slightly acidic environment,
such as found in the lysosomes, in order to be optimally active. There-
fore, cysteine cathepsins were initially considered as intracellular en-
zymes, responsible for the non-speciﬁc, bulk proteolysis in the acidic
environment of the endosomal/lysosomal compartment, where they
degrade intracellular and extracellular proteins [17,21]. However,
this view is rapidly changing.
2.1. Localization and main properties
The majority of cathepsins are ubiquitously expressed in human
tissues such as cathepsins B, H, L, C, X, F, O and V. Their expression
proﬁle indicates that these enzymes are involved in a normal cellular
protein degradation and turnover. In contrast, cathepsins K, W and S
show a restricted cell or tissue-speciﬁc distribution, indicating their
more speciﬁc roles. For example, cathepsin K is highly expressed in
osteoclasts, in most epithelial cells and in the synovial ﬁbroblasts in
rheumatoid arthritis joints [22]. Among the matrix-degrading en-
zymes, cathepsin K is the only enzyme for which an essential role in
bone resorption has been unambiguously documented in mice and
humans [23]. Cathepsin W (also lymphopain) is predominantly
expressed in CD8+ lymphocytes and natural killer (NK) cells
[24,25]. However, when cathepsin W expression has been downregu-
lated using the shRNA approach, its essential role in the process of
cytotoxity has been excluded [26]. Cathepsin S is predominantly
expressed in the professional antigen-presenting cells (APCs), such
as the dendritic cells (DCs) and B-cells [27]. In addition, cathepsin V
(also named L2) is highly homologous to cathepsin L, but in contrast
to the ubiquitously expressed cathepsin L, its expression is restricted
to thymus and testis [28,29]. However, recent studies have shown
that active cathepsins are also localized in other cellular compart-
ments, such as the nucleus, cytoplasm and plasma membrane. It
was thus shown that the catalytically active cathepsin L variants lo-
calized to the nucleus play a role in the regulation of cell-cycle pro-
gression [30] and the proteolytic processing of the N-terminus of
the histone H3 tail [31,32]. In addition, it was shown to interact
with the histones H2A.Z, H2B, H3 and the protease inhibitor steﬁn B
[33]. These studies and the nuclear localization of cathepsin F [34]
and possibly other cathepsins, provide the ﬁrst evidence that histones
may be very important substrates of cathepsins, thus opening up a
new role for these enzymes.
Moreover, there is sufﬁcient evidence that the speciﬁc physiolog-
ical functions of the cathepsins might be at least partially attributed
to their differences in localization inside and outside the cells
[9,35,36]. This is consistent with the recent advances in the ﬁeld of
proteases that led to a new concept, based on proteases as important
signaling molecules involved in the controlling mechanisms in many
normal and pathological processes [37–39].Cysteine cathepsins are optimally active in a slightly acidic pH and
are mostly unstable at neutral pH. When cathepsins are outside the
lysosomes or extracellularly they can be relatively rapidly irreversibly
inactivated at neutral pH [40]. An exception is cathepsin S, which is
stable at a neutral or slightly alkaline pH, thus retaining most of its ac-
tivity [41]. The inactivation of cathepsin L, the most unstable of the
cathepsins at neutral pH, was found to be a ﬁrst-order process and
the rate of the process decreased with the substrate concentration
that conferred some protection [42]. In cathepsin B, an irreversible
loss of activity accompanied by structural changes was observed.
The enzyme was destabilized by increasing the ionic strength and
the content of organic solvent [43]. However, after the binding of hep-
arin to cathepsin B through an interaction with its occluding loop, the
enzyme was partially protected from alkaline-pH-induced inactiva-
tion as a consequence of the restriction of the enzyme ﬂexibility,
which makes stronger contacts within the molecule [44,45]. In addi-
tion, it was recently suggested that catalase may participate in the
protection of extracellular cysteine cathepsins against peroxidation
[46].
The extracellular localization of cysteine cathepsins often coin-
cides with their increased expression and/or activity, indicating that
pH is not the sole factor responsible for their activity. Twenty years
ago, it was demonstrated that cathepsin B, from normal or tumor tis-
sues degraded puriﬁed extracellular-matrix components, type IV col-
lagen, laminin and ﬁbronectin, under both acid and neutral pH [47].
Cathepsins with strong elastolytic and collagenolytic activities are
now known to be chieﬂy responsible for the remodeling of the extra-
cellular matrix (ECM), thus contributing to various pathologies. The
ECM consists of elastins, collagens and proteoglycans, which have
all been identiﬁed as the cathepsin's substrates [48]. Elastin was
found to be cleaved by the cathepsins K, L, S, F, V and B, although
they differ in their elastolytic activitiy. Cathepsin V was thus found
to be the most potent enzyme, followed by the cathepsins K, S, F, L
and B [49,50]. It was further demonstrated that the elastolytic activi-
ties of the cathepsins V and K could be inhibited by ubiquitously
expressed glycosaminoglycans (GAGs), such as chondroitin sulfate,
through the formation of cathepsin-GAG complexes. In contrast, ca-
thepsin S, which does not form complexes with chondroitin sulfate,
is not inhibited, thus suggesting that there might exist some speciﬁc
regulation of the elastolytic activities of cathepsins by GAGs.
The most potent mammalian collagenase is cathepsin K (also
known as cathepsin O2) which, in contrast to the cathepsins B, L
and S, is highly expressed in osteoclasts [51,52], suggesting that it
plays a special role in bone resorption under normal and pathological
conditions [52]. Cathepsin K forms collagenolytically highly active
complexes with GAGs, with different GAGs competing for the binding
to the enzyme [53]. Some of them, such as chondroitin and keratan
sulfate, enhance the collagenolytic activity of cathepsin K, whereas
heparan sulfate or heparin selectively inhibits this activity. Moreover,
GAGs potentially inhibit the collagenase activity of cathepsins L and S
[53]. In addition, the speciﬁc inhibition of the collagenase activity of
cathepsin K by negatively charged polymers, such as polyglutamates
and oligonucleotides, without affecting the overall proteolytic activity
of the protease was observed [54]. It was suggested that during the
interaction between cathepsin K and polymers, collagen degradation
can be speciﬁcally inhibited, while its non-collagenolytic activities re-
main unchanged.
Although there is major evidence that various proteins can be de-
graded in vitro by cathepsins in acidic pH, there are scarce data about
their intracellular physiological substrates. One of the main reasons
for this is the cathepsin's instability and the loss of activity due to ir-
reversible unfolding [40,55]. The ﬁrst, well-established, intracellular
substrate of cathepsins was the proapoptotic Bcl-2 homolog protein
Bid, which was initially found to be processed by the lysosomal ex-
tract, thereby triggering cytochrome c release from mitochondria
and apoptosis [56]. There is signiﬁcant redundancy among the
Fig. 1. 3D schematic representation of the substrate-binding sites of papain-like prote-
ases along the active-site cleft. The representation is based on the proposed revised
deﬁnition of substrate-binding sites based on the crystal structures of substrate-
mimicking inhibitors bound to the protease's active sites [11]. The substrate-binding
sites of the papain-like proteases are located on the left (S1, S3, S2′) and right
(S2, S1′) side of the active-site cleft in accordance with the standard view orientation.
According to papain numbering, L-domain loops include residues Gln19-Cys25 and
Arg59-Tyr67 whereas R-domain loops contain residues Leu134-His159 and Asn175-
Ser205, respectively. The active-site residues Cys25 and His159 and the disulphide
Cys22-Cys63 are indicated.
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system Bid was found to be efﬁciently processed by the cathepsins B,
K, L and H to a proapoptotic form [57]. This ﬁnding was conﬁrmed in
various cellular models [57,58]. Moreover, it was found that, in
addition to Bid, cathepsins simultaneously degrade the antiapoptotic
Bcl-2 family proteins, such as Bcl-2, Bcl-xL, Mcl-1 and XIAP, thereby
triggering apoptosis in a synergistic manner [58]. However, there
are numerous biological processes in which cathepsins play an im-
portant role, but their substrates have not been identiﬁed so far.
This part of the review will not focus on the well-known basic prop-
erties of cysteine cathepsins, which are presented elsewhere [9].3. Structure and speciﬁcity
Understanding the interactions between cysteine cathepsins and
their substrates has been and remains the main challenge in the re-
search on cysteine cathepsins. Papain served as the model in the pio-
neering work of Schechter and Berger [59], in which they proposed
the nomenclature for the positions of the substrate residues (P) and
the subsites (S) where they bind to the surface of a protease. The po-
sitions and subsites were numbered in both directions from the sci-
sille bond between the residues P1 and P1′ onwards, where the
non-primed side refers to the N-terminal part and the primed side
to the C-terminal part of the substrate. In their pioneering work,
they found that adding residues to peptides longer than 7 alanine res-
idues does not affect the kinetics of their degradation and concluded
that there are seven substrate residues binding into seven subsites
from S4 to S3′. Three decades later, we revised the deﬁnition of the
substrate binding sites using an insight provided by the crystal struc-
tures of the complexes with small-molecule, substrate-mimickingFig. 2. 3D-based sequence alignment of the mature form of cysteine cathepsins. (A) The struc
a representative member of the papain-family, was done with the program MAIN [363]. The
[70], cathepsin F (1m6d) [73], cathepsin H (8pch) [67], cathepsin K (1mem) [65], cathepsin
and papain (9pap) [61]. According to cathepsin L numbering, the residues that form the sub
(I136-H163, N187-A214), are boxed and highlighted in light gray. (B) The structure-based se
ture of human cathepsin L (1icf) [74] using the Expresso (3D-Coffee) program [364]. In bot
percase letters whereas the non-conserved residues are indicated in lowercase letters. Ident
residues Cys25 and His163 are indicated by an asterisk.inhibitors [11]. These structures show that a substrate binds along
the active-site cleft in an extended conformation (Fig. 1).
Cysteine cathepsins exhibit broad speciﬁcity, thus cleaving their
substrates preferentially after basic or hydrophobic residues. This is
true not only for synthetic but also for protein substrates and consis-
tent with their roles in intracellular protein degradation [17]. The in-
formation about their speciﬁcity is mostly gathered on a case-by-case
basis, which limits their applicability. Nevertheless, within the past
decade some substantial progress has been made in the way we un-
derstand the speciﬁcity of cysteine cathepsins, in the variety of ap-
proaches applied and in the study cases where speciﬁcity has been
utilized to extract new knowledge.
3.1. Structures of cathepsins
The crystal structure of papain, a cysteine protease from Carica
papaya [60,61], was among the ﬁrst dozen protein crystal structures
to be determined. Together with actinidin [62], these two structures
provided the ﬁrst insight into their three-dimensional (3D) structure.
Later developments enabled the isolation of cysteine cathepsins, such
as cathepsin B, H, L, S, X, C, from various tissues, while the rest of the
cathepsins were expressed in various expression systems. In the
1990s the crystal structure of human cathepsin B was determined
[63]; this was followed by cathepsins L [64], K [65,66], H [67], X
[68], V [69], C [70,71], S [72] and F [73].
A 3D-based sequence alignment of the mature form of the nine
cysteine cathepsins with a known 3D structure exhibits conservation
of the active-site residues (Cys25 and His163, cathepsin L number-
ing), those residues interacting with the main chain of the bound sub-
strate, (Gln19, Gly68, Trp183), the N-terminus Pro2 and certain Cys
residues as well (Fig. 2A). Even though the 3D structures of the
remaining two human cysteine cathepsins, O and W, are still un-
known, a 3D sequence alignment carried out independently using
the crystal structure of human cathepsin L as a template [74] shows
the same conservation pattern (Fig. 2B).
The papain fold is shown in Fig. 3 using cathepsin L [74], as a typical
representative of the cysteine cathepsin endopeptidase. It is composed
of two domains, referred to as the left (L-) and right (R-), in accordance
with the standard view. The L-domain contains three α-helices. The
longest, i.e., the vertical helix, known also as the central helix, is over
30 residues long. The R-domain is a kind of β-barrel with the front
strand(s) forming a coiled structure. At the bottom, the barrel is
enclosed by an α-helix. The reactive site histidine is located at the top
of the sheet forming the barrel. The two-domain interface opens at
the top, forming the active-site cleft. In its center are the reactive site
residues, Cys25 and His163, each coming from a different domain. The
reactive site cysteine is located at the N-terminus of the central helix
of the L-domain, whereas the histidine is located within the β-barrel
residues of the R-domain. These two catalytic residues form the
thiolate-imidazolium ion pair, which is essential for the proteolytic ac-
tivity of the enzymes.
The active-site surface is composed of the residues coming from
four loops located on both domains (Figs. 1, 2A). The two L-domain
loops are short and cross-connected with a disulﬁde bond. The two
R-domain loops are much larger and form the lid of the β-barrel hy-
drophobic core. The substrate binds along the active-site cleft in an
extended conformation [11,75]. Its side chains make alternating con-
tacts with the L- and R-domains. The two loops on the L-domain andtural alignment of eight human cysteine cathepsins, porcine cathepsin H and papain, as
PDB codes of the structures are as follows: cathepsin B (1huc) [63], cathepsin C (1k3b)
L (1icf) [74], cathepsin S (1glo) [72], cathepsin V (1fh0) [69], cathepsin X (1ef7) [68],
strate-binding site, within the L-domain loops (Q19-C25, Q60-L69) and R-domain loops
quence alignment of human cathepsins O andWwas guided using the known 3D struc-
h cases the leading sequence was human cathepsin L (1icf) [74] and it is shown in up-
ical residues are shown as dots and the gaps are marked by the dash symbol. Active site
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Fig. 3. Fold of the mature form of cysteine cathepsins–endopeptidases. The fold of the
two-chain form of native cathepsin L (1icf) [74] is shown in the green ribbon representa-
tion. Theparts corresponding to the secondary structure elements,α-helices andβ-sheets,
are shown in blue and red color, respectively. The side chains of the reactive-site cysteine
(Cys25) and histidine (His163) are indicated in a ball-and-stick representation.
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the P3, P1 and P2′ residues, whereas the loops and residues of the
R-domain provide the binding surface for the P2 and P1′ residues.
An exception to this is the P2 residue. According to our model [75],
the P2 residue interacts with both domains. Its main-chain atoms
form an antiparallel hydrogen-bonding ladder with Gly68, while the
side-chain atoms bind into the S2 pocket formed at the two-domain
interface. The alternate positioning of the side chains suggests that
there may be a cooperativity effect between the residues oriented to-
ward the surface, in particular the P1 and P2′ appear to be close
enough to be able to interact. However, the experimental evidence
for the latter is still lacking.
Most cysteine cathepsins exhibit a predominantly endopeptidase
activity, whereas cathepsins X and C are exopeptidases only. Cathep-
sin C is an aminodipeptidase [70] and cathepsin H is, in addition to
an endopeptidase, an aminopeptidase [67]. Cathepsin B is an endo-
peptidase and a carboxydipeptidase [63], whereas cathepsin X is a car-
boxymonopeptidase [68]. The crystal structures revealed that
exopeptidases contain additional structural features that modify the
active-site cleft [63,67,70] (Fig. 4). Whereas in endopeptidases (cathep-
sins F, L, K, S and V) the active-site cleft extends along the whole length
of the two-domain interface, in exopeptidases (cathepsins B, C, H and
X) additional features reduce the number of binding sites [75]. In theFig. 4. Additional features of cysteine cathepsins–exopeptidases. Chain traces of exo-
peptidases cathepsins B, X, H and C are indicated in blue, yellow, green and red color,
respectively, over the surface of the endopeptidase cathepsin L (1icf) [74].case of carboxypeptidases, substrate binding is governed by the loops
that ﬁll the active-site cleft on the primed sides. These loops in both car-
boxypeptidases, the occluding loop of cathepsin B and the mini-loop of
cathepsin X, utilize histidine residue(s) to dock the C-terminal carboxylic
group of the peptidyl substrate. In contrast, cathepsins H and C utilize re-
gions from their propeptide parts in order to provide features that ﬁll
the active-site cleft on the non-primed sides. They use carboxylic groups
of the main- and side-chain residues to dock the positively charged
N-terminus of the peptidyl substrates. In cathepsin H the carboxylic
group is located at the C-terminus of an eight-residues-long peptide
[67], part of the propeptide, termed the mini-chain, which remains at-
tached to the body of the enzyme after its activation. However, in cathep-
sin C, the carboxylic group comes from the D1 side chain positioned at
the N-terminus of a whole additional domain, called the exclusion do-
main, which ﬁlls the active-site cleft [70]. Interestingly, in both amino-
peptidases, glycosylation appears crucial for stabilizing the structure of
these additional features and simultaneously ﬁlls the active-site cleft to
tighten the substrate binding.
3.2. Understanding substrate binding
While in the exopeptidases additional features inserted into the
endopeptidase scaffold deﬁne how many residues will bind on the
primed or non-primed side of the active-site cleft, understanding
the preferences for the peptidyl substrate side chains is a signiﬁcantly
more subtle matter.
The 3D structures have shown that the substrates bind in the
active-site cleft in an extended conformation. The superposition of
the structures provided support for only three well-deﬁned substrate
binding sites, S2, S1 and S1′, where the substrate residues interact
with the enzyme by the main- and side-chain interactions (Fig. 1).
Among these only the S2 site forms a pocket. In the positions outside
this region, there are only side-chain interactions. The spread of resi-
due positions across the active-site cleft on the non-primed side dem-
onstrates that the S3 and S4 binding sites are not really sites. More
appropriately, they are described as areas in which the substrate res-
idues individually ﬁnd their most favorable binding position [11,75].
On the primed binding side, there is still a limited structural insight
into the substrate binding. Data are provided by the synthetic
epoxysuccinyl-based inhibitors CA030, CA074 and NS134 complexes
with cathepsin B [76–78]. Their binding revealed the position of the
P1′ and P2′ residues. However, the information therein is also limited.
On one hand it is redundant as the P1′-like and P2′-like residues are
essentially the same in all structures. On the other hand, their infor-
mation is biased. The P2′-like residue docks its C-terminal carboxylic
group against the side chains of the His110 and His111 positioned
within the occluding loop of the cathepsin B. Since the occluding
loop is speciﬁc for cathepsin B, in other cathepsins the positioning
of the P2′ residue may be different.
Hence, there are only three deﬁned substrate binding sites (S2, S1,
S1′), where the amino acid residues of the substrate interact with the
main- and side-chain atoms at the surface of the enzyme (Fig. 1). In
the case of cathepsin B the main-chain interactions are offered by
the occluding loop histidines, while in the others there are no recog-
nizable exposed residues provided to serve as a dock for the main-
chain atoms of the substrate residues beyond S2 and S1′. Therefore,
these sites were recommended to be termed as areas [11]. Clearly,
in the absence of docking partners for the main-chain atoms, these
binding areas provide more opportunities for different binders. They
may, however, reduce the selectivity of the substrate.
3.3. Substrate binding sites
The substrate speciﬁcity of a protease is a delicate interplay of the
interactions between the surface of the protease and its substrates.
Studies trying to reveal this interplay are based on two
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lationship and (ii) studies of the substrate speciﬁcity, and a combina-
tion of these two approaches has been used for the past 20 years to
tackle the speciﬁcity of cysteine cathepsins for target proteins. In
the ﬁrst approach, the residues of interest located in the sequence
and 3D structure of a protease are mutated to reveal their relevance
and role in certain interactions. In the second approach, the enzymes
are left intact, but the substrates are manipulated in size and compo-
sition. The synthetic substrates include naturally occurring amino
acid residues as well as non-natural amino acid residues. Within the
frame of these studies are also the degradation studies of true protein
substrates by proteomic approaches. The latter are increasing in im-
portance because in in vitro experiments they get as close to the nat-
urally occurring events as is currently possible.
3.3.1. Structure–function relationship
Although considerable information about protease function can be
gained through a structure–function relationship, studies of cysteine
cathepsins were mainly performed using the substrate-speciﬁcity ap-
proach [10,11,79]. The majority of studies performed in the 1990s
were mostly focused on cathepsin B, which was the ﬁrst cathepsin
for which the crystal structure was determined [63]. The structure
of the enzyme [63] revealed that part of the S2 pocket is formed by
Glu245, a unique residue found only in cathepsin B but not in other
cathepsins. Its mutation to glutamine showed the importance of pro-
cessing the substrate with an arginine in the P2 position, but had no
effect on the phenylalanine substrates [80]. Another example is a mu-
tation at the S1 site of cathepsin B, which made the site more favor-
able for glycine, corresponding to the glycine-favorable papaya
protease IV (glycyl endopeptidase) [81]. Although not entirely linked
with the subsite speciﬁcity, the mutations of the histidine residues in
the occluding loop, as well as the deletion of the loop, revealed the
importance of the loop and the two histidine residues for the endo-
peptidase activity of cathepsin B [82,83]. A similar attempt was
made to understand the differences between the S2 sites of the ca-
thepsins L and K [84]. Double mutations of the S2 pocket of cathepsins
K (Y67L/L205A) and L (L67Y/A205L) induce a switch of their enzyme
speciﬁcity towards small selective inhibitors and peptidyl substrates,
conﬁrming the crucial role of residues at positions 67 and 205. How-
ever, both mutants, the cathepsin-K-like cathepsin L as well as the
cathepsin-L-like cathepsin K, were not capable of degrading collagen.
This indicated that introducing the proline tolerance alone did not
convert the cathepsin L to a collagenase, while abolishing the proline
selectivity in cathepsin K prevented it from degrading the collagen. A
similar follow-up study addressed the cathepsin K chondroitin bind-
ing site [85]. These example studies demonstrated that we have a
basic understanding of how speciﬁcity is encoded in the structure.
However, this understanding is still not sufﬁcient to enable us to pre-
dict the selectivity for substrates based on the sequence and atomic
structure of the cysteine cathepsins.
3.3.2. Discovery of selective substrates
With the switch from in vitro biochemical studies to physiological
studies in a complex biological millieu, the access to highly selective
substrates was found to be crucial for monitoring the activities of in-
dividual cysteine cathepsins in biological samples. The focus on sub-
strate studies therefore shifted to the discovery of substrates
speciﬁc for individual cathepsins. These studies use peptidyl libraries
combined with the positional scanning of individual positions, mostly
one at a time [86]. The survey below is a summary of a few examples,
which are indicative of the extensive research in the past decade. The
summary is organized on the basis of individual cathepsins.
Cathepsin B. Although numerous studies on cathepsin B speciﬁcity
have been performed in the past [79,80,87], a recent high-throughput
study demonstrated that arginine is indeed the most suitable residue
in the P1 position [88]. Moreover, based on the screening of the P3 toP1′ sites, the Abz-GIVRAK(Dnp)-OH peptide was found to contain the
most favorable residues for cathepsin B.
Cathepsin X. The development of substrates and their analysis [89]
were crucial for clarifying that cathepsin X is a carboxymonopepti-
dase only. As a result, the question about its additional dicarboxypep-
tidase [90] and endopeptidase activities has been resolved. The
ambiguity very likely resulted from the presence of impurities in the
samples, either obtained by isolation from a natural source (cathepsin
B) or by expression in the proform with the leftovers of the cathepsin
L as the activating enzyme.
Cathepsin K. The substrate speciﬁcity of cathepsin K has also been
extensively studied as the enzyme is an important drug target for the
treatment of osteoporosis. Among the mammalian cysteine cathep-
sins, cathepsin K was found to have a unique preference for a proline
residue in the P2 position, the primary determinant of its substrate
speciﬁcity [91]. As a result of such screening, the highly selective
Abz-HPGGPQ-EDDnp substrate was identiﬁed. The selectivity of the
substrate primarily depends on the S2 and S2′ site speciﬁcities and
the ionization state of the histidine in the P3 position. Its hydrolysis
was completely abolished in the cathepsin-K-deﬁcient cell lysates, in-
dicating its usefulness for monitoring cathepsin K activity in physio-
logical ﬂuids and cell lysates. Another screen of the S3–S3′ site
speciﬁcity using Abz-KLRFSKQ-EDDnp as the template showed that
the requirements of the S3–S1 sites are more restricted than those
of the S1′–S3′ sites [92]. In addition, it was found that positively
charged residues are favored in the P1 position, with glycine being al-
most equally well accepted. At the S3 site, positively charged residues
were readily accepted, whereas the other sites had less pronounced
preferences. However, when a proline was used in the P2 position it
conferred speciﬁcity for cathepsin K [92].
Cathepsin S. When screening cathepsin S using a template based
on the Ii sequence, clear preferences for groups of amino acid residues
were observed in the positions P3, P1 and P1′ [93]. Based on these re-
sults, highly cathepsin-S-selective peptides were developed. On this
basis, the authors suggested that the observed cleavage sites in Ii
might be of relevance for its in vivo processing [93]. In a follow-up
study, it was shown that the speciﬁcity of cathepsin S was mainly de-
termined by the S2, S1′, and S3′ sites. At the P2 position the hydro-
phobic valine, methionine and norleucine residues were clearly
preferred. Similarly, hydrophobic branched side chains were pre-
ferred at the P1′ position. The resulting GRWHTVGLRWE-Lys(Dnp)-
DArg-NH2 substrate with the cleavage site between Gly7 and Leu8
was claimed to be selective for cathepsin S more so than for cathep-
sins B, H, L and X [94]. The same authors have also conﬁrmed that
the substrate processing in endosomal fractions of antigen-
presenting cells was abolished in the presence of LHVS (morpholi-
nurea-leucine-homophenylalanin-vinyl sulfone-phenyl), a selective
inhibitor of cathepsin S. In a similar attempt to distinguish cathepsin
S from other cathepsins, a substrate was derived on the basis of its
putative physiological substrates, i.e., the insulin β-chain and the
class-II-associated invariant chain (CLIP) [95]. The resulting Abz-
LEQ-EDDnp (Abz= ortho-aminobenzoic acid; EDDnp=N-[[2,4-dini-
trophenyl]ethylenediamine]) peptide was capable of differentiating
cathepsin S from the cathepsins L, B, V and K.
Cathepsin V. When a substrate screen was made using cathepsins L
and V, it was found that the cathepsin V S1 and S3 sites exhibit a
broad speciﬁcity, while cathepsin L has a preference for positively
charged residues in the same positions. The S2 sites of both enzymes
were found to require hydrophobic residues with a preference for Phe
and Leu. On the other hand, the S1′ and S2′ sites in both cathepsins
were found to be less speciﬁc [96].
The listed examples lack a systematic approach that would not be
restrained by the limited variability of the substrate composition, nor
by the conﬁned list of targets used in the selection process. However,
novel approaches are on the way. An attempt that was considerably
less restrained by substrate selection was the high-throughput
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brary derived from natural proteins [97]. Unrestrained by the length
of the peptide, the screen revealed cathepsin K's preference for the
aspartate at the P5′ position. This speciﬁcity is believed to be relevant
for the recognition of collagen substrates. Yet another way to deter-
mine the substrate speciﬁcity of cysteine cathepsins is to use a pep-
tide phage library. Very recently, it has been reported that a
cathepsin-L-like enzyme from the tick Rhipicephalus (Boophilus)
microplus has a preference for leucine or arginine at the P1 position
[98]. Similar attempts will certainly shed light on the novel aspects
of the substrate speciﬁcity of cysteine cathepsins.
3.4. Small-molecule inhibitors of cysteine cathepsins
The discovery of an epoxysuccinyl-based inhibitor E-64 (L-trans-
Epoxysuccinyl-leucylamido(4-guanidino)butane), was very impor-
tant for the research on cysteine cathepsins [99]. It selectively alkyl-
ates the reactive site cysteine and remains covalently bound to the
enzyme. Because it reacts almost exclusively with the reactive site
cysteine of papain-like proteases, it has immediately become a widely
used indicator of the proteolytic activity of cysteine cathepsins. To-
gether with its derivatives that have improved cell-permeability
properties, it was of immense importance for progress in understand-
ing the function and properties of cysteine cathepsins, ranging from a
titration of their activity to an assessment of their activity in cell ly-
sates, cultures and living organisms. E-64 is a non-selective inhibitor
of all the cysteine cathepsins, with the exception of cathepsin C,
which is only weakly inhibited. In addition, E-64 also efﬁciently in-
hibits calpain [100]. The exploitation of its scaffold led to the seminal
contribution of Katunuma's group, who developed the ﬁrst speciﬁc
inhibitors of cathepsin B, CA030, CA074 and their analogs [101,102].
The crystal structure of cathepsin B with CA030 (ethyl-ester of
epoxysuccinyl-L-Ile-L-Pro-OH), a CA074 analog [76] and later with
CA074 in a complex with bovine cathepsin B [77], have shown that
these inhibitors bind into the primed side (sites S1′ and S2′) of the
active-site cleft in the direction of the substrate. These structures
have conﬁrmed that the carboxylic group of proline is indeed respon-
sible for binding to the occluding loop histidines, His110 and His111,
which were held responsible for the binding of the C-terminal car-
boxylic group of the peptidyl substrate. The alignment of the E-64
and CA030 binding geometries indicated that the epoxysuccinyl
group possesses an internal symmetry with two C-terminal carboxyl-
ic groups to which both amino acid residues can be attached. The idea
of using epoxysuccinyl as a building block that allows simultaneous
access to the non-primed as well as the primed side of the active-
site cleft was successfully adopted in the development of inhibitors
of cathepsin B [103,104] as well as the inhibitors of cathepsins K, L
and S [105,106]. The predicted binding geometry of the double-
headed inhibitors has been conﬁrmed by the crystal structures of
papain-CLIK complexes as the model for cathepsin L [107] and the ca-
thepsin B-NS-134 complex [78]. There are several, more detailed, pa-
pers on this subject worthy of further reading [75,108,109].
Additional uses of the epoxysuccinyl-based inhibitors include the
activity-based probes developed by Bogyo's group, mentioned
below. Leupeptin, which is found in bacteria, was another inhibitor
known from the 1970s [110]. It is an aldehyde that covalently binds
to nucleophilic serine and cysteine residues at the active site of the
cysteine and serine proteases. Due to its protease-class non-speciﬁc
interactions it was less widely used than E-64. However, its reaction
with the active site of cysteine proteases is reversible and allows a
reactivation of the enzyme, while the attached residues can provide
selectivity [111,112]. There are a number of reactive groups, also
called “warheads”, which interact with more than one class of prote-
ase. For example, one of the pioneers of the synthesis of protease in-
hibitors, Elliott Shaw, exploited diazomethane as the reactive group
[113–115].The covalent interactions with the active site either point into the
non-primed region or, as in the case of the epoxysuccinyl group, can
extend to both sides. The epoxysuccinyl group is a useful concept
for the inhibition of endopeptidases (see above) as well as for the car-
boxypeptidases cathepsins B [101–104] and X [116]. However, for the
aminopeptidases cathepsins C and H this concept would be difﬁcult to
apply due to their two C-termini. To achieve selectivity for cathepsin-
C dipeptidyl constructs with acyloxymethyl ketones, ﬂuoromethyl
ketones and vinyl sulfones were therefore developed [117]. On the
other hand, the selectivity for cathepsin H would be conﬁned to a sin-
gle binding subsite, S1. Inhibitors with limited selectivity were also
synthesized using chloro- and ﬂuoro-methyl ketones as the reactive
groups attached to a single amino acid residue [114].
For endopetidases and carboxypeptidases no such restraints on
the non-primed side of the active-site cleft apply. Therefore, there
were numerous developments. The list of reactive groups used is
rather extensive: acyloxymethyl ketones [118], vinyl sulfones
[119,120], nitriles [121,122], azepanone-based [123] and allyl-
sulfones [124]. More information can be found in an excellent over-
view [125]. There are also constructs that extend across the active-
site cleft without a covalent interaction and are not degraded, e.g.,
the cyclic ketones [126]. Lately, nitriles have been shown to give the
best results and they have also been used in all clinical candidates
[127]. The versatility of the small-molecule compounds is not con-
ﬁned like that of the peptidyl substrates and it does not directly ad-
dress the subsite speciﬁcity in terms of the biological function and
the role of cysteine cathepsins; therefore, this review does not at-
tempt to provide any in-depth look at their selectivity. It should be
mentioned that a number of inhibitors have been crystallized in com-
plexes with cysteine cathepsins and their structures have been deter-
mined. At present there are 160 deposited structures corresponding
to cathepsins, mainly they are cysteine proteases in complexes with
small-molecule inhibitors. The drug-discovery processes, predomi-
nantly targeting cathepsins K, L and S, are underway. A few of these
developments have already entered clinical trials [37].
3.5. Activity-based probes
Activity-based probes (ABPs) are substances that interact with the
active site of an enzyme to report on its activity. Their sophisticated
chemistry makes it possible to characterize the enzyme function di-
rectly in native biological systems [128]. ABPs usually carry a report-
er, such as biotin, or a quencher-ﬂuorophore pair, which gets
activated upon a reaction with the target enzyme.
Fluorescent probes based on the epoxysuccinyl- and acyloxymethyl-
ketone reactive groups enabled imaging in cells as well as non-invasive
optical imaging of cathepsins B and L in mice [129,130]. In addition,
ABPs for cathepsin X have also become available [116].
Until recently, ABPs targeting cysteine proteases were suicidal in-
hibitors, which remained attached to the enzyme after forming a co-
valent bond with the reactive site cysteine. However, a novel
approach termed “reverse design”, built on the existing selective in-
hibitors of cysteine cathepsins and their subsequent conversion into
substrates as the activity probes of proteases in vivo, was established
[131]. The conversion of the inhibitors of cathepsins K and S by the re-
placement of the active-site-directed functional electrophylic group
with a peptidyl unit and with the addition of a ﬂuorophore and a
quencher resulted in cell-permeable ABPs, which revealed the endo-
lysosomal localization of cathepsins L and S. In these studies cathep-
sins B, L, K and S were used to evaluate the selectivity of the probes.
Due to the non-suicidal nature of the activity probe, the physiology
of the cells under investigation is potentially less disturbed. More-
over, such activity-based probes can be used for the validation of
the effectiveness of activity-modulating compounds such as drug can-
didates in cells and in in vivo systems in a time-dependent manner
[132].
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It has been some time since the test for proteolytic activity was
based on the degradation of insulin. Nowadays, we try to understand
how proteases hydrolyze their physiological substrates. The recent
knowledge about the biological targets of cysteine cathepsins has large-
ly come from identifying the origin of genetic disorders and, conse-
quently, gene-knockout studies. There is a signiﬁcant redundancy of
cysteine cathepsins due to their co-localization and broad speciﬁcity.
Although most of the cysteine cathepsins do not have a speciﬁc role,
they possess a proteolytic potential to cleave a number of substrates.
However, it is likely that speciﬁc roles are linked to speciﬁc interactions
between proteases and substrates. For example, cathepsins B, H, K, L,
and S cleave kininogen, thereby releasing the kinin peptide; however,
only cathepsin K was shown to be able to cleave kinin at the naturally
occurring cleavage site, supporting the above idea [133,134].
It should be kept in mind that cysteine cathepsins co-localize and
therefore work in concert. Due to these limitations, only those specif-
ic, non-redundant roles could be revealed and conﬁrmed by the ab-
sence of a particular cathepsin. Here we have made an attempt to
divide the protein substrate hydrolysis into classical, i.e., conﬁned to
endosomes/lysosomes or secretory lysosomes, and non-classical, i.e.,
taking place outside these organelles, and correspondingly named
the substrates.
As seen below, apart from the cathepsin roles in antigen presenta-
tion and in granule protease activation, most of the speciﬁc physio-
logical roles under investigation take place in non-classical locations
and environments. Among these are the collagen degradation by ca-
thepsin K, thyroglobulin processing and thyroid hormone release by
various cathepsins, histone H3 processing by mouse cathepsin L and
the role of cathepsin X in integrin processing and T-cell signaling.
A rather simple mechanism of the classical pathway appears to be
that of the cathepsin C interaction with substrates. Its role is to grad-
ually remove two consecutive residues from protein N-termini. As
shown by the gene-knockout studies, a number of serine proteases
from immune and inﬂammatory cells are activated by cathepsin C
in the granules in this way [135].
Cysteine cathepsins also play a crucial role in adaptive immunity.
Cathepsin S is crucial for the processing of the invariant chain in bone-
marrow-derived antigen-presenting cells such as dendritic cells and
macrophages [136], while the human V and mouse L are required for
Ii processing in thymus. In addition, cathepsins generate peptides,
which are presented to MHC class-II molecules. Cathepsin L was found
indispensable for the generation of a speciﬁc peptides repertoire in cor-
tical thymic epithelial cells, which is required for CD4+ T cell positive
selection in thymus [137]. Considering the role of cathepsin S, an at-
tempt was made to reveal the substrate speciﬁcity of cathepsin S by
screening a peptide library [93]. For the purposes of validation the pat-
tern of the cleavage sites on the Ii polypeptide was compared with the
results of the peptide library screen, and, not surprisingly, some similar-
ities were found. However, the cleavage sites in the invariant chain
were numerous, so the question remains as towhether cathepsin S sim-
ply chops the Ii into smaller peptides or does cathepsin S perform a spe-
ciﬁc cleavage. Since cathepsins V/L were found to be crucial for the
processing of the thymus MHC class-II Ii complex, it is evident that sev-
eral proteases can do the same job. More recently, a new pathway for
prohormone processing mediated by the secretory vesicle cathepsin L
was described [138,139].
Glycosaminoglycans play a crucial role in the formation of com-
plexes between cysteine cathepsins and their protein substrates.
GAGs have thus been shown to regulate the collagenolytic activity
of human cysteine cathepsins [53,140,141]. Furthermore, for the col-
lagenase activity of cathepsin K, its complex formation with chon-
droitin sulfate is mandatory [140]. In the cartilage, cathepsin K
alone is capable of providing the source for GAGs by removing them
from aggrecan [142]. The insight into the mechanism of this ratherunique relationship was revealed by the crystal structure of the chon-
droitin sulfate-cathepsin K complex and the accompanying biochem-
ical study [143]. In the crystal, several cathepsin K molecules bind to a
single chondroitin sulfate at a site distant from the active site. This
work suggested that in the cathepsin K-hydrolysis of collagen the
role of chondroitin sulfate is to bring together and align several ca-
thepsin K molecules in a way that makes possible the cleavage of
the triple collagen helix. The chondroitin thus provides a scaffold for
the association of cathepsin K molecules. This effect is not shared by
cathepsin L [85]. Mutations in cathepsin K, which modiﬁed the chon-
droitin binding site in cathepsin K into cathepsin-L-like, decreased
the collagenolytic activity of the protein. In the crystal structure of
the complex between cathepsin-L-like cathepsin K and chondroitin
sulfate, the latter still binds to cathepsin K; however, not in the
same way as in the structure with native cathepsin K. To summarize,
these studies have revealed the relevance of chondroitin sulfate bind-
ing to cathepsin K for collagene proteolysis. Nevertheless, modifying
the binding site for chondroitin into cathepsin-L-like has not removed
the collagenase activity. This indicates that cathepsin K possesses ad-
ditional features that enable it to cleave collagen efﬁciently.
Gelatin, partially degraded and unfolded collagen, can, however,
be cleaved by several cathepsins [140]. Similarly, cathepsins L and S
can release GAGs from cartilage proteins such as aggrecan [142] and
there is evidence that cathepsin L participates in bone resorption
[144]. These ﬁndings suggest that a number of cathepsins participate
in bone resorption and remodeling. However, it has only been shown
for cathepsin K that its presence in the organism is vital for the oste-
oclast resorption and that its inhibition has a strong potential to treat
osteoporosis. Quite possibly it is the only cathepsin capable of un-
winding the collagen triple helix.
A further insight into the activity of cathepsin K was provided by
kinetic and spectroscopic studies, which provided evidence for there
being two states of cathepsin K, depending on the pH of the media
[145]. This is reminiscent of the cathepsin B exo- and endopeptidyl
activity [146], which was believed to be a result of the dissociation
of ionizing groups in the binding cleft. When the structure of cathep-
sin B became available [63], it was evident that the occluding loop
must be displaced in order to enable the endopeptidase activity of
the enzyme. This was ﬁnally conﬁrmed by mutations in the occluding
loop, including the removal of its parts [82,83]. In contrast to the exo-
peptidase cathepsin B, the cathepsin K fold does not provide an obvi-
ous structural feature on the surface of cathepsin K, which would
trigger a change of state and thereby affect the substrate kinetics in
a pH-dependent manner. As a possible mechanism, the oligomeriza-
tion of cathepsin K has not been excluded by the experimental data.
However, it remains open whether this behavior is consistent with
the model of cathepsin K to form a “beads on a string” structure, as
earlier suggested [143].
Another example that sheds light on substrate hydrolysis by ca-
thepsins is hormone release in the degradation of thyroglobulin
[147]. Despite a general belief to the contrary, it was shown that ca-
thepsins are capable of processing thyroglobulin under neutral and
oxidizing conditions. Cathepsins B, K, L and S were thus found to gen-
erate distinct fragments from thyroglobulin. Moreover, the thyroid
hormone thyroxine was liberated by the action of cathepsin S under
extracellular conditions, while cathepsins B, K and L were most efﬁ-
cient under endo-lysosomal conditions, suggesting that the biological
role of a protease may depend on the local environment.
Yet another non-classical role involves cathepsin L in the cleavage of
histone H3 in the nucleus [31]. Based on the assumption that this was a
rather speciﬁc interaction, itwas anticipated that the binding of amodel
substrate peptide into the active site might provide an insight into the
speciﬁcity of this interaction. A rather long peptide (derived from the
histoneH3 sequence 19–33)was therefore co-crystallizedwith an inac-
tive mutant of the human cathepsin L [148]. However, only the binding
of three residues into the non-primed binding sites at the cathepsin L
Fig. 5. Procathepsin B fold. The propeptide part of human procathepsin B (2pbh) [163] is
shown as a chain trace over the surface of themature part of the enzyme. Theα-helices are
shown in red color. The surfaces of the reactive-site residues, cysteine and histidine, are
marked with yellow and green color, respectively.
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should encourage further attempts to gain amore detailed structural in-
sight into the interactions between cysteine cathepsins and their phys-
iological substrates.
Cathepsins were also found to participate in processes such as the
modulation of T-cell migration. This process combines cathepsin tar-
geting outside endosomes and subsequent proteolysis at the target
location. The extracellular function of cathepsin X, the enzyme sug-
gested to be involved in this process, may include binding to integrins
via an RGD motif in its proregion, which further suggests an activa-
tion mechanism of the enzyme at a location outside the endosome.
It has been further suggested that the attachment of migrating cells
to extracellular matrix components is modulated [149]. Moreover, ca-
thepsin X was found to cleave β2 integrin, thereby demonstrating an-
other way of regulating T-cell migration [150]. There are indications
that cathepsin X removes the C-terminal residues of LFA-1, a β2 integ-
rin, thereby increasing its afﬁnity for the adaptor protein talin
[151,152]. The subsequent cleavages result in the intermediate as
well as the high-afﬁnity LFA-1. The intermediate afﬁnity form can as-
sociate with α-actinin 1, while the high-afﬁnity form is crucial for the
T-cell migration. Although not described in more details, cysteine ca-
thepsins were shown to participate in the regulation of antimicrobial
molecules by inactivation of the secretory leucoprotease inhibitor
[153] and, even though in part disputed [154], in the processing of vi-
ruses, such as cathepsin L in the processing of the corona virus [155].
4. Regulation
Under normal conditions in healthy organisms, cells use various
mechanisms to prevent potentially harmful and uncontrolled proteo-
lytic activity, including the compartmentalization of cathepsins with-
in the lysosome or other organelles, zymogen activation, pH, the
regulation of their activities by small-molecule inhibitors and various
endogenous protein inhibitors, or a combination of all these factors
for an optimal enzyme function [14,21,156]. Lysosomal cathepsins
contribute to these processes by the irreversible cleavage of the pep-
tide bonds with limited or random proteolysis accompanying the pro-
tein degradation. In the remainder of the review we will focus on
zymogen activation and the regulation by protein inhibitors, although
other aspects are also discussed.
4.1. Zymogen activation
Lysosomal cathepsins are synthesized as preproenzymes. The
cleavage of the N-terminal signal peptide occurs during the passage
to the endoplasmic reticulum in parallel with the N-linked glycosyla-
tion. After the removal of the signal peptide, the propeptide assists
in the proper folding of the enzyme and targeting to the endosomes/
lysosomes using a speciﬁc mannose-6-phosphate receptor (M6PR)
pathway, simultaneously acting as an inhibitor to prevent any inap-
propriate proteolytic activity of the zymogen [157–159]. Dissociation
of the bound, immatureM6PR occurs in themildly acidic environment
of the endosomes. After removal of theN-terminal propeptide, thema-
ture proteolytically active cathepsins are released. These mature en-
zymes occur as single-chain or double-chain forms, without affecting
their catalytic activity. The two-chain enzymes remain connected by
disulphide bridges [160].
Further progress in understanding the nature of zymogen activation
was obtained from the procathepsin structures. The crystal structures of
human and rat procathepsin B [161–163], human procathepsin L [164],
human procathepsin K [165,166] and human procathepsin X [167]
showed that the propeptide chain folds on the surface of the enzyme
in an extended conformation and runs through the active-site cleft, in
the opposite direction to the substrate, thereby blocking the access of
the latter to the active site, which is already formed in the zymogen
(Fig. 5). In the structure of most proenzymes, the hydrophobicinteractions, salt bridges and hydrogen-bonding interaction in the pro-
peptide and between the propeptide and themature enzymeexists. The
exception is the structure of cathepsin X, in which the propeptide binds
covalently to themature enzyme with a disulphide bridge between the
cysteine residue in the propeptide and the active-site cysteine, thus pre-
venting any autocatalytic processing [167]. However, it can be pro-
cessed in vitro under reducing conditions by cathepsin L [168].
In other cathepsins the proteolytic removal of the N-terminal pro-
peptide, resulting in the activation of the enzyme, is catalyzed by differ-
ent proteases such as cathepsin D and various cysteine proteases
[169,170], or autocatalytically under acidic conditions [171–174]. Some
early studies suggested that autocatalytic processing is a unimolecular
process [171,172], while others proposed inter- and intra-molecular
mechanisms [173,175]. This enigma has been recently clariﬁed. It is
now clear that the auto-activation of cathepsins is a combination of a
unimolecular and a bimolecular process [176]. Procathepsin B possesses
a low catalytic activity that is, nevertheless, sufﬁcient to trigger the auto-
catalytic activation of the zymogen. This activity is the result of the pro-
peptide dissociation from the active-site cleft as the ﬁrst step in this
process, which is in fact the only unimolecular step in the process
[177]. In the next step, which is already bimolecular, this catalytically ac-
tive zymogen molecule processes and activates another procathepsin
molecule in one ormore steps. Themature cathepsinmolecules generat-
ed in this way then initiate a chain reaction leading to a rapid activation
of the remaining procathepsinmolecules. Taken together, only endopep-
tidases such as the cathepsins B, H, L, S and K can be activated by the re-
moval of the propeptide, whereas the true exopeptidases, such as the
cathepsins C and X, required endopeptidases, such as the cathepsins L
and S, for their activation [178].
The autocatalytic activation of cathepsins is substantially acceler-
ated in the presence of negatively charged molecules, such as GAGs
and dextran sulfate, suggesting that GAGs are involved in the in vivo
processing of cathepsins [179]. Similarly, GAGs accelerate the auto-
catalytic removal of the propeptide and the subsequent activation of
cathepsin B. These ﬁndings suggest that GAGs may play a physiolog-
ical role in the activation of procathepsin B [179]. The results were
conﬁrmed by the autocatalytic activation of procathepsin S in the
presence of GAGs [180].
Propeptides, which are removed during the processing of cysteine
cathepsins, have been shown to be potent inhibitors of their cognate
enzymes in vitro. The ﬁrst such example was the synthetic propeptide
of cathepsin B, which was found to inhibit cathepsin B at pH 6.0 with
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This further suggested that during the activation at acidic pH the pro-
peptide dissociates from the surface of the enzyme, thereby facilitat-
ing the activation, and this was then later experimentally conﬁrmed
[176]. Subsequently, the recombinant cathepsin L propeptide was
found to inhibit cathepsin L with Ki=0.088 nM and cathepsin S
with Ki=44.6 nM, whereas no inhibition of cathepsin B or papain
was observed, providing the ﬁrst evidence for propeptides acting as
selective cathepsin inhibitors [182]. Further studies conﬁrmed these
ﬁndings and demonstrated that propeptides exhibit a limited selec-
tivity of inhibition against their cognate enzymes [183]. Moreover, ca-
thepsin S propeptide was found to be rapidly degraded by cathepsin L
[184]. The latter, linked with the acidic, pH-induced unfolding and
dissociation of the procathepsin B propeptide [176], suggests that
the propeptides released during the zymogen activation are degrad-
ed, and as a result lose their inhibitory role. However, it should be
noted that in the procathepsin structure the propeptide is covalently
bound to the enzyme (Fig. 5), whereas all the in vitro studies men-
tioned above were performed with isolated peptides. Therefore,
these studies do not necessarily reﬂect the in vivo situation. For
more in-depth information about the structural aspects and function
of the propeptides see [160,185,186].
In spite of their similar biological function, the propeptides of cyste-
ine cathepsins show very little similarity in their amino acid sequence.
This is in striking contrast to the strong overall homology between the
majority of theirmature forms. However, this can probably be explained
by the need for a selective inhibition of their cognate enzymes during
trafﬁcking to the endolysosomal compartments and subsequent degra-
dation after the processing to prevent the sustained inhibition of the
cathepsins in the lysosomes. A sequence analyses of the family of
papain-like cysteine proteases led to the recognition of two distinct sub-
families, designated as cathepsin-L-like and cathepsin-B-like proteases,
which can be distinguished by both the propeptide andmature enzyme
structure [186,187]. Themain difference between the subfamilies exists
in the sequence of the propeptides and their length [17]. Propeptides of
the cathepsin L subfamily (cathepsins L, V, K, S, W, F and H) contain a
propeptide of about 100 residues, with two conserved motifs: a highly
conserved ERFNIN motif and the GNFD motif. The former is lacking in
the cathepsin B subfamily, while the propeptides of cathepsins C, O
and X lack the ERFNIN motif. The propeptide of cathepsin X contains
only 38 residues and is the shortest of the cathepsins [188,189]. In con-
trast, the cathepsin F propeptide with 251 residues is the longest of the
human cathepsins and contains, in addition, an N-terminal cystatin-like
domain [190,191]. The propeptide of cathepsin C contains 206 residues
[192]. Interestingly, after the removal of the 87 propeptide residues dur-
ing proteolytic activation, the remaining 119 residues become part of
the structure of the mature cathepsin C responsible for its dipeptidyl
peptidase activity, known as the exclusion domain [70].
4.2. Protein inhibitors of cysteine proteases
The major regulators of the mature cysteine cathepsins are their
endogenous protein inhibitors, cystatins, thyropins and serpins,
among others. Basically, they are competitive, reversible, tight-
binding inhibitors, preventing substrate binding to the same active
site. Some basic principles of the kinetics of the interaction between
inhibitors and proteases, as well as their physiological role, are dis-
cussed. In short, based on their physiological role, they are divided
into emergency and regulatory inhibitors [14]. Typical emergency in-
hibitors are cystatins, which are separated from their target enzymes
and primarily act on escaped proteases [14] or proteases of invading
pathogens [193]. This was also demonstrated for thyropins [194].
Regulatory inhibitors not only block but also modulate the protease
activity. Moreover, they are often co-localized with their target en-
zymes and are classiﬁed into threshold-type, buffer-type and delay-
type inhibitors. Buffer-type inhibitors keep proteases complexed inthe absence of substrates and release them in the presence of sub-
strates, thus preventing inappropriate proteolysis. Propeptides of ly-
sosomal cathepsins most likely belong to this type of inhibitors
(reviewed in [17,181]). All these four types of inhibitors (emergency,
threshold, buffer and delay) are important to keep the necessary bal-
ance under normal physiological conditions [14].
4.3. Classiﬁcation and main properties
The ﬁrst classiﬁcation of the protein inhibitors of papain-like cyste-
ine proteases, the cystatin superfamily, into three families was based
on proteins homologous to chicken cystatin, the ﬁrst inhibitory protein
with a known amino acid sequence [195]. In addition, to close the se-
quence relationship with at least a 50% sequence identity [196], the
new criteria included the absence or presence of two or nine disulphide
bonds [197]. However, the rapidly increasing number of cystatins from
various origins resulted in a new division into four types on the basis of
the presence of one, two or three copies of the cystatin-like domains
and the presence or absence of disulphide bonds [198]. While the ﬁrst
three types, namely, steﬁns, cystatin and kininogens, are inhibitory pro-
teins [198–202], the fourth type consists of non-inhibitory homologs of
cystatins such as fetuins [203] and histidine-rich glycoprotein [204],
containing two cystatin-like domains [205]. However, in evolution
they lost their inhibitory activity due to mutations in the structurally
important regions [206]. A very important step was the introduction
of the MEROPS database as an integrative source of information, ﬁrstly
the peptidases [207,208]. Then, for protein peptidase inhibitors, a single
systemof nomenclature on the basis of similarities at the amino acid se-
quence level and three-dimensional structures was introduced [209].
They were grouped into clans, families and individual inhibitors, corre-
spondingly. The cystatin family is assigned to three subfamilies, I25A,
I25B and I25C of clan IH, while thyropins are assigned to family I31 of
clan IX [209,210]. The classiﬁcation of protein peptidase inhibitors is
continually under revision as can be seen from the MEROPS website at
http://merops.sanger.ac.uk. Therefore, the cystatins will be discussed,
grouped into types [197,198], which is more convenient with respect
to the present status in the ﬁeld.
4.3.1. Steﬁns (type 1 cystatins)
Steﬁns are single-chain proteins of ~100 amino acid residues, syn-
thesized without signal peptide and they lack carbohydrates and dis-
ulphide bonds. They are primarily intracellular proteins [199], but can
also be detected in body ﬂuids [211]. Steﬁns are present in most
major eukaryotic subgroups [206]. Originally, two representatives of
this group, steﬁns A and B, were found in various mammals, including
humans [199]. In addition, bovine steﬁn C has been identiﬁed as the
ﬁrst Trp-containing steﬁn with a prolonged N-terminus [212]. Steﬁns
belong to the subfamily I25A of the cystatin protein family [210].
4.3.2. Cystatins (type 2 cystatins)
Cystatins are more widely distributed proteins than steﬁns
[202,206]. They are single-chain proteins of ~115 amino acid residues.
In contrast to steﬁns, cystatins contain a signal peptide responsible for
secretion through the cell membrane to the extracellular milieu, recog-
nized as extracellular proteins [199,200,211]. Currently, seven mem-
bers of this type of inhibitor have been identiﬁed: cystatin C, salivary
cystatins (cystatins S, SA and SN), cystatin D, cystatin E/M and cystatin
F (leukocystatin). All type 2 cystatins contain two highly conserved
intra-molecular disulphide bridges, with the exception of human cysta-
tin F, which possesses an additional disulphide bridge, thus stabilizing
the N-terminal part of the protein [213]. The human type 2 cystatins
are grouped into subfamily I25B of the cystatin family I25 [210].
4.3.3. Kininogens (type 3 cystatins)
Kininogens have been known for several decades as the precursor
molecules of the kinins found predominantly in the blood plasma of
78 V. Turk et al. / Biochimica et Biophysica Acta 1824 (2012) 68–88mammals and in some other species. Although kinins could be re-
leased through two major pathways involving either the plasma
kallikrein-kinin system or tissue kallikrein, an alternative route may
involve cysteine cathepsins [214]. Kininogens are multifunctional
and multidomain glycoproteins comprising three distinct types:
high-molecular-weight kininogen (HK), low-molecular-weight kini-
nogen (LK) and T-kininogen (TK), an acute phase protein only
found in rats [215]. Both human HK and LK are products of the
same gene, resulting from the alternative mRNA splicing [216],
while TK is encoded by the TK-gene [217]. The mature kininogens
are single-chain proteins with multiple domains [218,219]. After
cleavage by kallikreins, they release the kinin segment and are con-
verted into two-chain proteins, a heavy- and a light-chain [218].
The heavy chains of HK and LK have an identical amino acid sequence,
whereas the light-chain of HK is much longer than that of LK
[199,200]. The molecular mass of LK is 51 kDa [220] and 84 kDa for
HK [221]. The heavy chains of HK and LK are composed of three tan-
demly repeated type 2 cystatin-like domains (domains 1, 2, 3) con-
taining eight disulphide bridges. Only the second and third domains
inhibit the papain-like proteases [222]. The inhibitory domains 2
and 3 are more closely related than domain 1. Both HK and LK bind
two molecules of various cysteine proteases including cathepsins
and cruzipain with high afﬁnity [220,221]. In contrast, in vitro studies
showed that the aspartic protease cathepsin D inactivates the third
domain of the human kininogen and cystatin C, suggesting a role for
cathepsin D in regulating the activity of cysteine cathepsins at acidic
pH [223]. It was recently demonstrated that HK regulates the endo-
thelial function, thus serving as a cardioprotective peptide [224].
Some other studies showed some novel function of kininogens, such
as the regulation of angiogenesis (reviewed in [225]). Like type 2
cystatins, the kininogens are grouped into subfamily I25B of the
cystatin family I25 [210].
4.3.4. Thyropins
The discovery that a fragment of the p41 invariant chain (p41Ii) as-
sociatedwithMHC class-II molecules inhibits cathepsin L [194,226,227]
suggested the appearance of a new family of protein inhibitors of cyste-
ine cathepsins. This ﬁnding was conﬁrmed by the discovery of a new
protein, equistatin, isolated from the sea anemone Actinia equina,
strongly inhibiting cathepsin L and papain [228] and human cathepsin
D [229]. The determined amino acid sequences of the equistatin [228]
and p41 fragment [227] showed no homology to cystatins, but a signif-
icant homology to thyroglobulin type-1 domains, which are present in
prohormone thyroglobulin [230]. Therefore, the name thyropins has
been suggested for this new group of proteins [231]. In equistatin, as a
three-domain protein, the N-terminal domain 1 is responsible for the
inhibition of papain-like proteases [228], whereas the second domain
inhibits cathepsin D [229,232]. Thyroglobulin type-1 domains are also
present in several functionally unrelated proteins [14]. Thyropins are
grouped into family I31 of clan IX [210]. More details can be found in
a recent review [233].
4.3.5. Other protein inhibitors
Some serpins, as typical inhibitors of serine proteins, can also in-
hibit cysteine proteases in cross-class inhibition [14]. The human
squamous cell carcinoma antigen-1 (SCCA1) is a potent inhibitor of
the cathepsins K, L and S [234], whereas hurpin speciﬁcally inhibits
only cathepsin L [235]. Similarly, the serpin endopin 2C selectively in-
hibits cathepsin L compared to elastase [236]. There are numerous
other cystatins or cystatin-related proteins that are expressed in
other tissues and types in humans and other mammals [237].
Several genes, including CRES (cystatin-related epididymal sper-
matogenic), testatin, cystatin-T, have been identiﬁed, but they lack
the highly conserved QXVXG region crucial for cysteine cathepsin's
inhibition. These genes are primarily expressed in the reproductive
tract, suggesting a cell-speciﬁc and regulatory function differentfrom cystatins. CRES proteins are classiﬁed as a new subgroup within
the type 2 cystatins (reviewed in [238]). Certainly, this group of pro-
teins deserves more detailed investigations in order to clarify their
function.
Gene-encoding cystatins have also been found in various parasitic
organisms. Their function is presumably to inhibit their own and host
proteases to enable parasite development. Cystatins have been found
in several ticks, which constitute the main vector of Lyme disease in
the USA and Europe. The two-cystatin transcripts are encoded by two
different genes in the tick Ixodes scapularis. Both expressed homologous
salivary proteins, sialostatin L [239] and sialostatin L2 [240], strongly
inhibited, almost equally, cathepsin L with Ki=4.7 nM and cathepsin
V with Ki=57 nM, while no inhibition of cathepsins B, X and C was ob-
served. Cathepsin L as collagenolytic enzyme hydrolyzes ECM proteins,
such as collagen and elastin, and it was shown that its collagenolytic ac-
tivity can be inhibited by chicken cystatin [241]. Consequently, it was
demonstrated that sialostatin L, by inhibiting the collagenolytic activity
of cathepsin L, displays an anti-inﬂammatory role and reduces the pro-
liferation of cytotoxic T-lymphocytes [239].
There are many other parasitic organisms containing speciﬁc
parasite-derived inhibitors, such as Plasmodium [242,243], Trypanosoma
cruzi [244], human ﬁlarial nematodes [245], and other parasitic organ-
isms [193], among others. Although there are numerous other cystatins
from plants and other organisms, it is beyond the scope of this review.
5. Mechanism of inhibition of cysteine cathepsins
Cystatins and steﬁns are tight-reversible binding protein inhibitors of
papain-like cysteine proteases (reviewed in [10,14,199,200,202,237]).
The interaction with their target enzymes can be very tight, a Ki value
of ~10 fM has been determined for the interaction between cystatin C
and papain [246]. An important step in the elucidation of the molecular
mechanism by which these protein inhibitors inhibit their target
enzymeswas the determination of the crystal structure of chicken cysta-
tin [247] and the successfully prepared recombinant human steﬁn B
[248] in a complex with S-carboxymethylated papain [249]. Both inhib-
itors, cystatin and steﬁn B, consist of a long, ﬁve-turn α-helix and a ﬁve-
stranded antiparallel β-pleated sheet, with an additional helix or strand,
respectively [247,249]. These structural data provided strong evidence
that there are three regions crucial for the interactionwith their cognate
enzymes: the amino terminus and two hairpin loops. An exposed ﬁrst
β-hairpin loop (comprising a highly conserved QVVAG region or similar
sequenceQXVXG) isﬂanked on either side by the projectingN-terminal
segment and the highly conserved second β-hairpin loop, which con-
tains the highly conserved Pro-Trp dipeptide. Both hairpin loops and
the amino terminus form a tripartite, mainly hydrophobic, wedge-
shaped edge, containing most of the conserved residues and segments
involved in binding, highly complementary to the active-site cleft of pa-
pain. The N-terminal truncated forms of chicken cystatin conﬁrmed the
crucial importance for binding of the residues preceding the conserved
Gly9 residue [250]. The hydrophobic side-chain interactions stabilized
the complex. In cystatin and steﬁn complexes the interactions in the
S2 subsite strengthen the complexes with papain considerably
[250–252]. However, it was reported that in spite of considerable simi-
larity between the structural feature of free steﬁn A in solution [253]
and the crystal of the homologous protein steﬁn B in complex with
papain [249], there are some important differences in the regions that
are crucial for protein binding, such as the ﬁve N-terminal residues
and the second binding loop [253]. Similarly, the comparison of the
chicken cystatin structure determined by X-ray crystallography [247]
and NMR [254] showed signiﬁcant differences in the structurally vari-
able segments of the polypeptide chain. These ﬁndings suggested that
the binding of cystatin/steﬁn type inhibitors cannot be satisfactorily
explained solely on the basis of the steﬁn B-papain complex [249].
The crystal structure of steﬁn A, in complex with the papain-like
exopeptidase cathepsin H showed some distinct differences [255]. The
Table 1
Interaction between some representative lysosomal cysteine proteases (human cathep-
sins, cruzipain and papain) and selectedmembers of the cystatin family (human cystatins,
chicken cystatin) and thyropins (p41 fragment).
Ki (nM)
Inhibitor Cathepsin B Cathepsin H Cathepsin L Cruzipain Papain
Steﬁn A 8.2 0.31 1.3 0.0072 0.019
Steﬁn B 73 0.58 0.23 0.060 0.12
Cystatin C 0.27 0.28 b0.005 0.014 0.00001
Cystatin D >1000 7.5 18 n.d. 1.2
Cystatin E/M 32 n.d. n.d. n.d. 0.39
Cystatin F >1000 n.d. 0.31 n.d. 1.1
Cystatin S n.d. n.d. n.d. n.d. 108
Cystatin SA n.d. n.d. n.d. n.d. 0.32
Cystatin SN 19 n.d. n.d. n.d. 0.016
Chicken cystatin 1.7 0.06 0.019 0.001 0.005
L-kininogen 600 0.72 0.017 0.041 0.015
p41 fragment >1000 5.3 0.002 0.058 1.40
Inhibitor constants (Ki) for human cystatins [200,201,261], chicken cystatin [200], and
p41 fragment [226,227]. n.d. (not determined).
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ly displays a cathepsin H mini-chain and distorted a small part of the
structure. The recently determined crystal structure of human steﬁn
A–cathepsin B complex indicated that the papain-like part of the ca-
thepsin B structure remains unmodiﬁed upon the binding of steﬁn A,
whereas the occluding loop residues are displaced [256]. Consequently,
cathepsin B can bind certain ligands along thewhole interdomain inter-
phase, such as inhibitors or substrates. On the other hand, cathepsin B is
poorly inhibited by kininogens due to the residues His110-His111 posi-
tionedwithin its occluding loop. The His110Ala cathepsin Bmutant, un-
like its His111Ala mutant, does not hydrolyze kininogens but forms a
tight-binding complex [257].
Although the interaction between cystatins and their target prote-
ases is primarily non-speciﬁc, cystatins are able to discriminate be-
tween endo- and exopeptidases, as a consequence of the differences
in the structures of the interacting regions of the enzymes, as already
explained. However, it was reported that mouse steﬁn A variants dis-
criminate between papain-like endopeptidases, such as cathepsins L
and S, and the exopeptidases cathepsins B, C and H. The interaction
with exopeptidases is several orders of magnitude weaker compared
to the human, porcine and bovine steﬁns [258]. Namely, bovine steﬁns
A, B and C inhibit rapidly and tightly endopeptidases such as papain,
cathepsin L and S in the pM range, whereas cathepsin B does so very
poorly [212,259,260]. Furthermore, it was shown that human cystatin
C, steﬁns B and chicken cystatin strongly inhibit the endopeptidase cru-
zipain from T. cruziwith Ki=1.4–72 pM [261].
Among the thyropins, it is the only very potent inhibitor of human
origin, the p41 fragment of which inhibits human cathepsin L with
Ki=1.7 pM [227]. This fragmentwas isolated in a complexwith cathep-
sin L [194] and its crystal structure was determined [74]. The structure
of the p41 fragment demonstrates a new fold consisting of two sub-
domains connected by disulphide bonds. The wedge-shaped and
three-loop arrangement of this fragment bound to the active-site cleft
of cathepsin L is reminiscent of the binding of cystatins [74], thus dem-
onstrating the ﬁrst example of convergent evolution observed in cyste-
ine protease inhibitors, similar to chagasin [262]. Recently, it has been
shown that the p41 fragment inhibits human cathepsins V, K, S and F
and mouse cathepsin L with Ki values in the nM range [263] in addition
to human cathepsin L [227] and cruzipain [226]. These ﬁndings suggest
that the regulation of the proteolytic activity of most of the cysteine
cathepsins by the p41 fragment has an important andwideranging con-
trol mechanism of antigen presentation [263]. Similar to the p41 frag-
ment, equistatin binds rapidly and tightly to papain and cathepsin L,
but with a lower afﬁnity to cathepsin B [228].
Some equilibrium constants for the dissociation of the complexes
between human cystatins and the p41 fragment and their target
papain-like enzymes are summarized in Table 1. The afﬁnity in Ki
values is due to the differences in the active-site regions of the
endo- and exopeptidases, as discussed above.
6. Evolution of cystatins
Early studies of the evolution of the cystatin superfamily were
based on a small sample of taxonomic diversity and diversity within
the cystatin superfamily [200,264]. Since then, the number of repre-
sentatives across themammals, plants, viruses and parasites increased
mainly due to the accumulation of mammalian and plant genomic se-
quences. In addition, several genes, including CRES (cystatin-related
epididymal spermatogenic), testatin and cystatin-T related to the
cystatins, were identiﬁed but lack consensus sites that are important
for inhibition [238]. Gradually, the numerous proteins containing
cystatin domain(s) have been discovered, resulting in a challenging
problem of their comprehensive evolutionary classiﬁcation. A detailed
analysis of more than 2100 prokaryotic and eukaryotic genomes pro-
vided strong evidence for the emergence of the cystatin superfamily
in the ancestors of eukaryotes [206]. A primordial gene duplicationresulted in only two ancestral eukaryotic lineages, steﬁns and cysta-
tins. While steﬁns remained the intracellular proteins responsible for
regulation of an endogenous protein turnover, cystatins gained a sig-
nal peptide and emerged as extracellular inhibitors responsible for
regulation of an exogenous protein turnover involved in host-
pathogen/parasite predator interactions. Therefore, steﬁns may func-
tion as inhibitors of endogenous cysteine proteases, whereas cystatins
function as inhibitors of exogenous cysteine proteases. It is notewor-
thy that intracellular steﬁns are more conserved than very divergent
extracellular cystatins. Moreover, the ﬁrst diversiﬁcation of cystatins
occurred in the ancestors of vertebrates when the ﬁrst orthologous
families emerged. This indicates that functional diversiﬁcation has
occurred in multicellular eukaryotes, often resulting in a loss of the
ancestral inhibitory activity, gaining novel functions in innate immu-
nity. Furthermore, the observed distribution of steﬁns and cystatins
in bacterial genomes is very limited. This suggests that the bacterial
steﬁns and cystatinsmay serve as emergency inhibitors, thus enabling
the survival of bacteria in the host, defending them from the host's
proteolytic activity by inhibiting cysteine cathepsins.
7. Physiological role
Originally, cysteine cathepsins were believed to participate exclu-
sively in terminal protein degradation during necrotic and autophagic
cell death. However, nowadays it is well established that they execute
numerous speciﬁc functions participating in important physiological
processes, such as MHC-II-mediated antigen presentation, bone
remodeling, keratinocyte differentiation, prohormones activation,
and others [13,17,18]. One of the most intriguing ﬁelds is the process-
es of adaptive immunity in which antigen processing and presenta-
tion play a major role. Cysteine cathepsins such as cathepsins L, S
[27,265,266], cathepsin F [267] and human cathepsin V [268], play a
crucial role by degrading the invariant chain and the responsible gen-
erated antigenic peptides during MHC class-II restricted antigen pre-
sentation, which are recognized by CD4+ T cells [269]. It has been
found that cathepsin V is highly homologous to cathepsin L and ex-
clusively expressed in human thymus and testis. This suggests that
cathepsin V is a protease that controls the generation of αβ-CLIP com-
plexes in human thymus in analogy to cathepsin L in mice [268]. The
observed inhibition of several cysteine cathepsins by a p41 fragment
might be an important and general control mechanism for antigen
presentation [263]. For further reading see [270–272]. There are sever-
al other physiological states, such as bone remodeling, angiogenesis and
prohormone activation, among others, in which cathepsins and their en-
dogenous inhibitors play an important role [9,17,18,139,273]. However,
an increase in the level of cathepsin expression and activity appears to
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such as neurological disorders, cardiovascular diseases, obesity, inﬂam-
matory diseases, such as rheumatoid arthritis, and cancer, among others.
It was recently shown that cathepsin K deﬁciency induces structural and
metabolic changes linked to learning and memory deﬁcits [274].
Obesity is an important risk factor for various metabolic and car-
diovascular disorders, the so-called “metabolic syndrome”where sev-
eral studies indicate the role of cathepsins L, S and K [275,276]. It was
documented that the pharmacological inhibition of cathepsins L
resulted in a reduced body weight in mice [277,278].
In cardiovascular diseases a crucial role is played by cysteine cathep-
sins, with their strong elastolytic and collagenolytic activity in ECM
remodeling. Consequently, they are implicated in the development of
arterial enlargements and aneurysm formation. Cysteine cathepsins
are differently expressed in various stages of atherosclerosis. Cathepsins
K and S were found as the ﬁrst cathepsins expressed in human athero-
sclerotic lesions [279]. On the other hand, deﬁciencies of both enzymes
in amousemodel reduce atherosclerosis [280,281]. Furthermore, it was
demonstrated that cathepsins B, K and S are expressed in cerebral aneu-
rysms, thus promoting their progression by the degradation of ECM in
arterialwalls. In contrast to the upregulated expression of these cathep-
sins, cystatin C expression was reduced with aneurysm progression,
suggesting that an imbalance between cathepsins and their inhibitors
may be responsible for the breakdown of ECM in arterial walls and
the rupture of cerebral aneurysms [282]. Recently, it was found that leu-
kocytic cathepsin S deﬁciency results in amarkedly altered plaquemor-
phology, reduced apoptosis and decreased collagen deposition, which
might be critical for plaque stability [283]. The pathological mecha-
nisms that are responsible for the degradation of arterial ECM are still
not well understood. For further reading, these reviews are suggested
[48,283].
There are several genetic disorders due to mutations in genes of
cysteine cathepsins and their protein inhibitors cystatins. Genetic
studies revealed that loss-of-function mutations in the cathepsin C
(DPPI) gene results in early-onset periodontitis and palmoplantar
keratosis, characteristics of Haim-Munk and Papillon-Lefevre syn-
dromes [284]. The location of missense mutations suggests, based
on structural studies, how they disrupt the fold and function of ca-
thepsin C [70]. In the cathepsin K gene there are at least ﬁfteen
known mutations in humans, thus resulting in cathepsin-K deﬁciency
and leading to pycnodysostosis [285]. Interestingly, mutation Y212C
causes the appearance of enzyme activity only against type-I collagen,
preserving its overall activity [286]. However, this mutation prevents
the formation of complexes between cathepsin K and chondroitin sul-
fate, which is crucial for collagenolytic activity.
Similarly, genetic disorders were also observed in protein inhibitors
cystatins. The abnormal formation of the human cystatin-C variant
(L68Q), formerly the γ-trace protein, resulted in cerebral haemorrage
with amyloidosis [287], now known as hereditary cystatin-C amyloid
angiopathy — HCCAA (reviewed in [288]). Our discovery that human
γ-trace is a protein inhibitor of cysteine cathepsins, human cystatin
[195,289], then termed cystatin C [290], was crucial for the understand-
ing of the formation of oligomeric proteins. Further studies revealed
that the dimerization of native human cystatin C occurs through a
three-dimensional domain-swapping mechanism, and suggest the
mechanism of its aggregation in the brain arteries of HCCAA patients
[291,292]. However, the ﬁbril formation of tetramers of human steﬁn
B under in vitro conditions involves a previously unknownprocess of in-
tramolecular contacts termed “hand shaking”, which occurs concur-
rently with the trans-to-cys isomerization of Pro74 [293]. A recent
review about the mechanisms of amyloid ﬁbril formation is focused
on domain-swapping [294].
The mutations on the cystatin B (steﬁn B) gene are involved in the
progressive myoclonus epilepsy of Unverricht-Lundborg Disease
(EPM1), an autosomal recessive neurodegenerative disorder [295].
Several mutations have been detected in the steﬁn-B gene and oneof them affects the conserved QVVAG region, which is crucial for
the binding to cysteine cathepsins [295]. Nevertheless, for functional
studies it is necessary to take into consideration the species differ-
ences between humans and mice [296,297]. Cathepsin F is a widely
expressed lysosomal enzyme. However, it is the only cysteine cathep-
sin whose inactivation based on cathepsin F−/− mice results into a
neurodegenerative disease termed neuronal ceroid lipofuscinosis
(NCL) and suggested its possible relation to late-onset NCL [268].
However, adult-onset patients did not reveal any mutations to date
[298,299].
7.1. Cysteine cathepsins in cancer
Cathepsins, in particular cathepsin B, were ﬁrst linked to cancer as
long as 30 years ago [300]. It is now clear that the cathepsins have an
important role in both tumor progression and invasion, which is sup-
ported by the numerous clinical reports and results from experimen-
tal mouse-cancer models [301–303]. Elevated cathepsin expression
and/or activity has been shown to be associated with cancer progres-
sion in a number of different types of tumors [304–309]. Moreover,
the level of cathepsin expression positively correlated with a poor
prognosis for cancer patients and was suggested to be a potential
prognostic marker [310–312]. In addition, serum cathepsin levels
have been positively correlated with metastasis [313]. The roles of ca-
thepsins in the individual tumor-biological processes were also con-
ﬁrmed ex vivo using cell-based systems. As such, the cathepsins B, L
and some others have been shown to promote the migration and in-
vasion of tumor cells [314–319]. In addition to their well-known
function associated with the ECM degradation and remodeling in
the tumor microenvironment, cathepsins were suggested to partici-
pate in the proteolytic cascade activation (Fig. 6). The activation of
pro-uPA and other proteases, which was demonstrated in vitro,
would thus potentiate their effect on the dissolution of the tumor ma-
trix and the basement membrane [320–323], which is a prerequisite
for invasion and metastasis. To fulﬁll these functions cathepsins
have to be localized at the extracellular space, in order to have access
to the bulk of potential targets and processes affecting tumor progres-
sion. As a conﬁrmation of cathepsin secretion, increased serum levels
of these proteases in cancer patients have been detected
[304,324–328]. Despite the extracellular functions of cysteine cathep-
sins, intracellular cathepsins could participate in tumor progression,
affecting processes acting both as pro-tumorigenic and anti-
tumorigenic [329]. As an example of intracellular pro-tumorigenic ac-
tivity, cathepsins could participate in intracellular collagen degrada-
tion [330–333]. Moreover, this role of cysteine cathepsins in normal
and malignant extracellular matrix degradation is in agreement
with the ﬁnding that the endocytic transmembrane glycoprotein
uPA receptor-associated protein directs the collagen IV for lysosomal
delivery and degradation [333]. On the other hand, cathepsins have
recently attracted considerable attention as potential mediators in
programmed cell death (apoptosis) [38], a key process in cancer de-
velopment and progresion [334]. However, evidence has been accu-
mulated for multiple scenarios of how cysteine cathepsins promote
cell death. For example, after their release from the lysosomes they
could engage the mitochondrial pathway of apoptosis by the activa-
tion of caspases indirectly through the degradation of the antiapopto-
tic Bcl-2 family members and the proteolytic activation of Bid (Fig. 6).
Moreover, their ability to cleave XIAP suggests their involvement in
the control of apoptosis, both upstream and downstream of mito-
chondria [58].
Another level of complexity is introduced by the fact that the pro-
teolytic activity of cysteine cathepsins is regulated by their endoge-
nous protein inhibitors, steﬁns, cystatins and serpins [14]. It has
been found that a higher level of cathepsin inhibitors in different
types of cancer correlates with a favorable prognosis for cancer pa-
tients [335,336]. On the other hand, an increased concentration of
Fig. 6. Mechanisms of the cysteine cathepsins involvement in cancer progression. Extracellular cysteine cathepsins promote tumor progression by initiating a proteolytic cascade
that results in the activation of a urokinase-type plasminogen activator (uPA), matrix metalloproteinases (MMPs) and plasminogen. Collectively, active proteases, including cyste-
ine cathepsins themselves, can degrade all of the components of the extracellular matrix, promoting tumor progression and metastasis. The degradation of cell-adhesion proteins
(e.g., E-cadherin) would additionally increase the disseminative ability of tumor cells. Alternatively, translocated into the cytosol cysteine cathepsins are shown to act as initiator
proteases in lysosome-mediated cell death through the degradation of antiapoptotic Bcl-2 family members and the proteolytic activation of Bid, engaging the mitochondrial path-
way of apoptosis.
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ly with shorter survival times [337,338]. Although a higher level of ca-
thepsin inhibitors may counterbalance the up-regulation of cysteine
cathepsins, their role in cancer remains poorly deﬁned, and this
calls for further investigations to be performed [339].
Additional evidence conﬁrming the important role of cathepsins in
cancer progression was provided by the use of cathepsins-knockout
technology and transgenic cancer models in small animals. In the
same year, two research groups have independently shown the effect
of major cathepsin/cathepsins depletion on tumor development, pro-
gression, and metastasis in two murine cancer models: (i) pancreatic
islet cell carcinoma (RIP1-Tag2) [340] and (ii) MMTV-PyMT mouse
mammary cancer [341], as summarized in Table 2. The depletion of
cathepsin B in both cancer models resulted in a signiﬁcantly reduced
tumor burden and a delay in the development of high-grade carcino-
mas. Furthermore, while in the RIP1-Tag2 model a signiﬁcant 44%
decrease in the proliferation of the tumor cells was detected, the prolif-
eration indexwas reduced in 10-week-oldmice by 12%, but not in mice
that were 14 weeks old. In contrast to the RIP1-Tag2 model, no differ-
ences in tumor vascularization and apoptosis have been detected in
the MMTV-PyMT model of breast cancer [341], which was conﬁrmed
by a follow-up report [342]. Moreover, it has been shown that the
genetic ablation of cathepsin B in primary MMTV-PyMT tumor cells
induces the membrane translocation of another carboxypeptidase, ca-
thepsin X, that restores the invasive capability of tumor cells and anni-
hilates the effect of the principal protease deletion at the level of lungTable 2
Summary of the effects of cathepsin B deletion on MMTV-PyMT and RIP-Tag2
tumorigenesis.
MMTV-PyMT
breast cancer
RIP1-Tag2
pancreatic cancer
Tumor volume 40% decrease 72% decrease
Histopathological
progression
Signiﬁcant delay of high-grade
carcinomas development
Signiﬁcant delay of invasive
carcinomas development
Cell proliferation Early stage cancer: 12% decrease
late stage cancer; no change
44% decrease
Apoptosis No change 229% increase
Vascularizalion No change 56% decreasemetastasis [341]. This ﬁrst report on such a cathepsin-compensation ef-
fect has been further conﬁrmed by the use of double cathepsin B and X
knockout mice crossed with the MMTV-PyMT mouse model, providing
evidence for the synergistic anticancer effects of both carboxypepti-
dases [342].
Despite the important role of cathepsins from tumor cells, there is
an increasing body of evidence conﬁrming the up-regulation of cyste-
ine cathepsins by cells of the tumor microenvironment, such as mac-
rophages [302,340,341]. The cancer state is currently viewed as a
product of its microenvironment [343]. Therefore, new technologies
that enable the targeting of the tumor microenvironment would rep-
resent an efﬁcient approach to cancer prevention and intervention
[344]. Indeed, such a technology was recently provided by the devel-
opment of a novel, targeted, drug-delivery system enabling the tar-
geting of both the tumors and their microenvironment [345].
Moreover, the targeting of JPM-565, a small-molecule inhibitor of
cysteine cathepsins, which was very potent in the treatment of pan-
creatic islet tumors in a mouse model [346], lacked any efﬁcacy in a
mouse breast-cancer model due to the very poor bioavailability of
the compound [347]. The respective anti-tumor therapy using JPM-
565 proved to be very successful, resulting in a signiﬁcant reduction
in tumor growth [345], thereby proving the concept of stroma target-
ing and the cathepsins as potent targets in cancer treatment. There-
fore, the application of selective inhibitors of cathepsins offers new
possibilities for the diagnosis and treatment of human diseases.
7.2. Cysteine cathepsins in rheumatoid arthritis
Rheumatoid arthritis (RA) is characterized by chronic synovial
joint inﬂammation and the inﬁltration of an activated CD4+ T cell
and APC, such as dendritic cells and macrophages [348]. It involves
a progressive destruction of the articular cartilage, eventually leading
to a loss of joint function. In addition to metalloproteases, such as col-
lagenases and aggrecanases, lysosomal cysteine cathepsins B and L
have been identiﬁed in synovial ﬂuids [349–352]. Furthermore, the
involvement of cathepsin B and L in bone degradation was demon-
strated by the selective inhibition of these enzymes [353]. In addition,
the expression of the potent ECM degrading enzyme, cathepsin K, was
found in synovial ﬁbroblasts from RA patients to correlate with the
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ﬁnding that the chondroitin sulfate found in synovial ﬂuids stabilizes
the cathepsin K activity and subsequently increases its collagenolytic
activity [355]. Very recently, it was reported that neither cathepsin B
nor cathepsin H serum levels were associated with this disease, while
the progression of destruction was associated with high serum levels
of the inhibitors steﬁn A and B and not cystatin C [356]. In addition, it
was found that cathepsin B and signiﬁcantly elevated cathepsin S
were detected in the synovial ﬂuid of RA patients [357]. Signiﬁcantly,
an elevated level of cathepsin S is consistent with its critical role in
the immune response. Recent developments in medical treatments
may contribute tomore effective and safe treatments of rheumatoid ar-
thritis and ostheoarthritis using speciﬁc inhibitors [358,359].
8. Perspectives
Over the past two decadeswe havewitnessed tremendous advances
in the understanding of the properties and structures of cysteine ca-
thepsins and their endogenous protein inhibitors cystatins; although
most of our knowledge has emerged only recently. The understanding
of the basic biology of these proteins under normal and pathological
conditions is constantly improving, although additional rules have yet
to be more precisely established. The application of genomic and prote-
omic approaches to identify new substrates of individual cathepsins un-
covers new roles for these enzymes in vivo [360,361]. New strategies for
the in vivo imaging of cysteine cathepsin activity for designing selective
enzyme activity-based probes are in progress. Computational ap-
proaches based on the three-dimensional structure of domain–domain
interactions involving cysteine cathepsins and their protein inhibitors
should provide a more comprehensive view of this biological system
[362]. By exploring the insights into the cysteine cathepsins biology of
humans, new emerging therapies in various diseases, such as cancer, in-
ﬂammatory diseases, neurological disorders, cardiovascular diseases,
and parasitic diseases, are developing with a high probability of being
incorporated into clinical trials.
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